Human papillomavirus genotype prevalence in invasive vaginal cancer from a registry-based population

Obstetrics and Gynecology

Volumn 123, Issue 4, 2014, Pages 817-821

  Sinno, Abdulrahman K ^a   Saraiya, Mona ^a   Thompson, Trevor D ^a   Hernandez, Brenda Y ^a   Goodman, Marc T ^a   Steinau, Martin ^a   Lynch, Charles F ^a   Cozen, Wendy ^a   Saber, Maria Sibug ^a   Peters, Edward S ^a   Wilkinson, Edward J ^a   Copeland, Glenn ^a   Hopenhayn, Claudia ^a   Watson, Meg ^a   Lyu, Christopher ^a   Unger, Elizabeth R ^a  

^a JOHNS HOPKINS UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

WART VIRUS VACCINE;

ADULT; AGED; ARTICLE; FEMALE; GENOTYPE; HUMAN; HUMAN PAPILLOMAVIRUS TYPE 16; HUMAN PAPILLOMAVIRUS TYPE 18; HUMAN PAPILLOMAVIRUS TYPE 33; MAJOR CLINICAL STUDY; MULTICENTER STUDY; POLYMERASE CHAIN REACTION; POPULATION RESEARCH; PREVALENCE; PRIORITY JOURNAL; REGISTER; SURVIVAL; TUMOR INVASION; VAGINA CANCER; VIRUS DETECTION; WART VIRUS;

ADENOCARCINOMA; ALPHAPAPILLOMAVIRUS; CARCINOMA, SQUAMOUS CELL; FEMALE; GENOTYPE; HUMAN PAPILLOMAVIRUS 16; HUMANS; KAPLAN-MEIER ESTIMATE; MIDDLE AGED; PROPORTIONAL HAZARDS MODELS; REGISTRIES; VAGINAL NEOPLASMS;

EID: 84898761854     PISSN: 00297844     EISSN: 1873233X     Source Type: Journal    
DOI: 10.1097/AOG.0000000000000171     Document Type: Article

References (21)

1. U.S. Cancer Statistics Working Group. United States Cancer Statistics: 1999-2010 Incidence and Mortality Web-based Report. Atlanta: U.S. Department of Health and Human Services, Centers for Disease Control and Prevention and National Cancer Institute; 2013. Available at: www.cdc.gov/uscs.
2. Siegel R, Naishadham D, Jemal A. Cancer statistics. 2013. CA Cancer J Clin 2013;63:11-30.
3. Stock RG, Chen AS, Seski J. A 30-year experience in the management of primary carcinoma of the vagina: analysis of prognostic factors and treatment modalities. Gynecol Oncol 1995;56:45-52.
4. Ries LAG YJ, Keel GE, Eisner MP, Lin YD, Horner MJ, editors. SEER survival monograph: cancer survival among Adults: U.S. SEER program, 1988-2001, patient and tumor characteristics. Bethesda (MD): National Cancer Institute, SEER Program, NIH Pub. No. 07-6215l; 2007.
5. Pride GL, Buchler DA. Carcinoma of vagina 10 or more years following pelvic irradiation therapy. Am J Obstet Gynecol 1977;127:513-7.
6. Wu X, Matanoski G, Chen VW, Saraiya M, Coughlin SS, King JB, et al. Descriptive epidemiology of vaginal cancer incidence and survival by race, ethnicity, and age in the United States. Cancer 2008;113(suppl):2873-82.
7. Daling JR, Madeleine MM, Schwartz SM, Shera KA, Carter JJ, McKnight B, et al. A population-based study of squamous cell vaginal cancer: HPV and cofactors. Gynecol Oncol 2002;84:263-70.
8. Ostrow RS, Manias DA, Clark BA, Fukushima M, Okagaki T, Twiggs LB, et al. The analysis of carcinomas of the vagina for human papillomavirus DNA. Int J Gynecol Pathol 1988;7: 308-14.
9. Kiyabu MT, Shibata D, Arnheim N, Martin WJ, Fitzgibbons PL. Detection of human papillomavirus in formalin-fixed, invasive squamous carcinomas using the polymerase chain reaction. Am J Surg Pathol 1989;13:221-4.
10. Ikenberg H, Runge M, Göppinger A, Pfleiderer A. Human papillomavirus DNA in invasive carcinoma of the vagina. Obstet Gynecol 1990;76:432-8.
11. Paavonen J, Jenkins D, Bosch FX, Naud P, Salmerón J, Wheeler CM, et al. Efficacy of a prophylactic adjuvanted bivalent L1 virus-like-particle vaccine against infection with human papillomavirus types 16 and 18 in young women: an interim analysis of a phase III double-blind, randomised controlled trial. Lancet 2007;369:2161-70.
12. Gargano JW, Wilkinson EJ, Unger ER, Steinau M, Watson M, Huang Y, et al. Prevalence of human papillomavirus types in invasive vulvar cancers and vulvar intraepithelial neoplasia 3 in the United States before vaccine introduction. J Lower Genit Tract Dis 2012;16:471-9.
13. Hariri S, Steinau M, Rinas A, Gargano JW, Ludema C, Unger ER, et al. HPV genotypes in high grade cervical lesions and invasive cervical carcinoma as detected by two commercial DNA assays, North Carolina, 2001-2006. PloS One 2012;7: e34044.
14. Okagaki T, Clark BA, Zachow KR, Twiggs LB, Ostrow RS, Pass F, et al. Presence of human papillomavirus in verrucous carcinoma (Ackerman) of the vagina. Immunocytochemical, ultrastructural, and DNA hybridization studies. Arch Pathol Lab Med 1984;108:567-70.
15. Koyamatsu Y, Yokoyama M, Nakao Y, Fukuda K, Saito T, Matsukuma K, et al. A comparative analysis of human papillomavirus types 16 and 18 and expression of p53 gene and Ki-67 in cervical, vaginal, and vulvar carcinomas. Gynecol Oncol 2003;90:547-51.
16. Ferreira M, Crespo M, Martins L, Félix A. HPV DNA detection and genotyping in 21 cases of primary invasive squamous cell carcinoma of the vagina. Mod Pathol 2008;21:968-72.
17. Steinau M, Patel SS, Unger ER. Efficient DNA extraction for HPV genotyping in formalin-fixed, paraffin-embedded tissues. J Mol Diagn 2011;13:377-81.
18. Wheeler CM, Kjaer SK, Sigurdsson K, Iversen OE, Hernandez-Avila M, Perez G, et al. The impact of quadrivalent human papillomavirus (HPV; types 6, 11, 16, and 18) L1 virus-like particle vaccine on infection and disease due to oncogenic nonvaccine HPV types in sexually active women aged 16-26 years. J Infect Dis 2009;199:936-44.
19. Brunner AH, Grimm C, Polterauer S, Hefler L, Stani J, Heinze G, et al. The prognostic role of human papillomavirus in patients with vaginal cancer. Int J Gynecol Cancer 2011;21:923-9.
20. Centers for Disease Control, Prevention (CDC). Human papillomavirus- associated cancers-United States, 2004-2008. MMWR Morb Mortal Wkly Rep 2012;61:258-61.
21. Gillison ML, Chaturvedi AK, Lowy DR. HPV prophylactic vaccines and the potential prevention of noncervical cancers in both men and women. Cancer 2008;113(suppl): 3036-46.